Dr. Hutcheon earned his medical degree from Case Western Reserve University School of Medicine. He then went on to complete his internship and residency from University of Pittsburgh Medical Center on the Internal Medicine-Clinical Scientist Track.
Case Western Reserve University: Dean's Scholarship, 2007-2011
Occidental College Department of Chemistry: Analytical Chemistry Award, 2001
Occidental College: Presidential Scholarship, 1998-2002
No More 'Code Black': Intervention to Improve Inpatient Flow at a Large Public Hospital Am J Med. 2018 Apr; 131(4):371-376. . View in PubMed
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC) Invest New Drugs. 2007 Oct; 25(5):445-51. . View in PubMed
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone Cancer. 2007 Aug 01; 110(3):556-63. . View in PubMed